NCT04358523View on ClinicalTrials.gov

A Study of the Relative Bioavailability of ASC18 Tablets vs Reference Tablets in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

March 20, 2020

Primary Completion Date

December 15, 2020

Study Completion Date

December 15, 2020

Conditions
Healthy
Interventions
DRUG

ASC18

ASC18：ravidasvir and sofosbuvir fixed Dose Combination 200 mg/400 mg

DRUG

ravidasvir and sofosbuvir

RDV 200 mg and SOF 400 mg

DRUG

ASC18

ASC18：ravidasvir and sofosbuvir fixed Dose Combination 200 mg/400 mg

Trial Locations (1)

410008

Xiangya Hospital Central South University, Changsha

Sponsors
All Listed Sponsors
lead

Ascletis Pharmaceuticals Co., Ltd.

INDUSTRY

NCT04358523 - A Study of the Relative Bioavailability of ASC18 Tablets vs Reference Tablets in Healthy Volunteers | Biotech Hunter | Biotech Hunter